6 news items
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
AUPH
5 Jun 24
on the safety and effectiveness of LUPKYNIS® (voclosporin), a second generation calcineurin
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024
AUPH
14 May 24
and safety and efficacy data of LUPKYNIS will also be presented.
Aurinia Pharmaceuticals Inc
Aurinia Reports Presentation Of Two Studies At The Annual Congress Of Clinical Rheumatology
AUPH
9 May 24
The data reinforce previous findings on the safety and effectiveness of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
AUPH
9 May 24
(CCR) East 2024 taking place in Destin, FL, May 9-12. The data reinforce previous findings on the safety and effectiveness of LUPKYNIS (voclosporin
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
AUPH
2 May 24
, the updated label no longer includes language indicating that the safety and efficacy of LUPKYNIS has not been established beyond one year. The label
pp4hi8g1id7lhb2goybbq99dnjmwjbhr4mt qzf3hbb2h3vr70xi5bu3vo6f
AUPH
30 Apr 24
The updated label no longer includes language indicating that the safety and efficacy of LUPKYNIS has not been established beyond one year
- Prev
- 1
- Next